TW202045505A - 用於疾病之治療之新穎化合物及其醫藥組合物 - Google Patents

用於疾病之治療之新穎化合物及其醫藥組合物 Download PDF

Info

Publication number
TW202045505A
TW202045505A TW109105861A TW109105861A TW202045505A TW 202045505 A TW202045505 A TW 202045505A TW 109105861 A TW109105861 A TW 109105861A TW 109105861 A TW109105861 A TW 109105861A TW 202045505 A TW202045505 A TW 202045505A
Authority
TW
Taiwan
Prior art keywords
compound
pyridin
pyrazolo
carboxylic acid
pharmaceutically acceptable
Prior art date
Application number
TW109105861A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬 尼可拉 艾倫 柏蒙
薩維亞 馬力 柏克
馬丁 丹尼爾 科瑪斯
艾內 瑪莉 強庫爾
菲迪克 吉爾柏 拉貝吉葉赫
拉摩斯 米立安 洛佩茲
萊布 陶斯 提摩
Original Assignee
比利時商葛萊伯格有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商葛萊伯格有限公司 filed Critical 比利時商葛萊伯格有限公司
Publication of TW202045505A publication Critical patent/TW202045505A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW109105861A 2019-02-25 2020-02-24 用於疾病之治療之新穎化合物及其醫藥組合物 TW202045505A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1902490.0 2019-02-25
GBGB1902490.0A GB201902490D0 (en) 2019-02-25 2019-02-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
TW202045505A true TW202045505A (zh) 2020-12-16

Family

ID=65998935

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109105861A TW202045505A (zh) 2019-02-25 2020-02-24 用於疾病之治療之新穎化合物及其醫藥組合物

Country Status (19)

Country Link
US (1) US20220144823A1 (cg-RX-API-DMAC7.html)
EP (1) EP3931191B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022525121A (cg-RX-API-DMAC7.html)
KR (1) KR20210134001A (cg-RX-API-DMAC7.html)
CN (1) CN113474344A (cg-RX-API-DMAC7.html)
AR (1) AR124749A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020229041A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016642A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130154A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021010485A2 (cg-RX-API-DMAC7.html)
ES (1) ES2963409T3 (cg-RX-API-DMAC7.html)
GB (1) GB201902490D0 (cg-RX-API-DMAC7.html)
IL (1) IL285751A (cg-RX-API-DMAC7.html)
MA (1) MA55074A (cg-RX-API-DMAC7.html)
MX (1) MX2021010093A (cg-RX-API-DMAC7.html)
PH (1) PH12021552032A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109157TA (cg-RX-API-DMAC7.html)
TW (1) TW202045505A (cg-RX-API-DMAC7.html)
WO (1) WO2020173739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物
WO2025143152A1 (ja) * 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル-ピラゾロ[1,5-a]ピリジン化合物、およびそのMYLK4阻害剤としての使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
CA2732520A1 (en) * 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ, インコーポレイテッド Pi3k阻害剤としてのヘテロアリールおよびその使用
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
EP3227286B1 (de) * 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
JP7175917B2 (ja) * 2017-04-27 2022-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 新規のalk2阻害剤及びbmpシグナル伝達の阻害方法

Also Published As

Publication number Publication date
CN113474344A (zh) 2021-10-01
PH12021552032A1 (en) 2022-11-14
WO2020173739A1 (en) 2020-09-03
IL285751A (en) 2021-10-31
SG11202109157TA (en) 2021-09-29
MA55074A (fr) 2022-01-05
JP2022525121A (ja) 2022-05-11
KR20210134001A (ko) 2021-11-08
GB201902490D0 (en) 2019-04-10
EP3931191A1 (en) 2022-01-05
EP3931191B1 (en) 2023-10-04
ES2963409T3 (es) 2024-03-27
AU2020229041A1 (en) 2021-10-21
CA3130154A1 (en) 2020-09-03
BR112021016642A2 (pt) 2021-11-03
MX2021010093A (es) 2021-09-21
CO2021010485A2 (es) 2021-08-19
US20220144823A1 (en) 2022-05-12
AR124749A1 (es) 2023-05-03

Similar Documents

Publication Publication Date Title
ES3043457T3 (en) Rip1 inhibitory compounds and methods for making and using the same
KR102824962B1 (ko) 헤테로시클릭 rip1 억제 화합물
RU2684641C1 (ru) Производные пиразолопиридина в качестве модуляторов активности tnf
JP6001048B2 (ja) チアゾロピリミジン化合物
KR20250172881A (ko) 글루코스-의존성 인슐린 분비 촉진 폴리펩티드 수용체 길항제 및 이의 용도
AU2026203216A1 (en) 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
CN117355532A (zh) 三并环类usp1抑制剂及其用途
US20240246932A1 (en) Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
JP2021526123A (ja) オートタキシン阻害剤とその使用
KR20140117427A (ko) 염증성 질환의 치료를 위한 신규의 다이하이드로피리미디노아이소퀴놀리논 및 그의 약학 조성물
WO2007037534A1 (ja) 2-へテロアリール置換インドール誘導体
CN109890827A (zh) 螺环化合物
PH12015502055B1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2021535164A (ja) 心筋サルコメア阻害剤
US10174021B2 (en) Substituted pyrazolo[1,5-A]pyridines and their use
JP2018138609A (ja) ナフチリジンジオン誘導体
US20250235510A1 (en) Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist peptides
KR20220002903A (ko) 과혈당증의 치료에 유용한 헤테로아릴(헤테로시클릴)메탄올 화합물
WO2016120850A1 (en) Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof
EP3931191B1 (en) Pyrazolopyridine derivatives as inhibitors of pask
EP1683798B1 (en) Fused polycyclic compounds having heterocycle and medicinal use thereof
ES2641469T3 (es) Compuesto de 2-piridona
KR101858881B1 (ko) 4-{4-[(1e)-4-(2,9-디아자스피로[5.5]운데스-2-일)부트-1-엔-1-일]-2-메틸벤질}-5-(프로판-2-일)-1h-피라졸-3-일 베타-d-글루코피라노시드 아세테이트
EP4522604A1 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
KR20230154382A (ko) 신규한 pim 키나아제 억제 화합물 및 이의 용도